Akero Therapeutics (AKRO)
(Real Time Quote from BATS)
$22.20 USD
+0.01 (0.05%)
Updated Jul 9, 2024 11:20 AM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Brokerage Reports
Akero Therapeutics, Inc. [AKRO]
Reports for Purchase
Showing records 41 - 60 ( 106 total )
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Recap: EFX Adaptive Phase 2b/3 Trial Design Begins to Take Shape; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Adding NASH Cirrhosis Opportunity and Post-Data Equity Raise to Our Model; PT to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We View 16-Week Biopsy Results of EFX as a Real Breakthrough in NASH; Raise PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in BALANCED Cohort C of Cirrhotic NASH Patients; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Must Read: Takeaways from Our NASH Expert Call with Dr. Eric Lawitz
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Managing Street Expectations - Figuring Out Biopsy Results - Part 1
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Recap: All Eyes on First NASH Biopsy Data for AKR-001 Next Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our GLP-1 Call with Dr. Juan Frias Today at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dial in Today to Part 1 of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Akero Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y